news
21 November 2018
Santhera Enters into Agreement to Acquire Option from Idorsia for Exclusive Sub-License of First-in-class Dissociative Steroid Vamorolone for Duchenne Muscular Dystrophy (DMD)
Share
For more information on the agreement and the clinical development of Vamorolone please clink link below: